Your browser doesn't support javascript.
loading
Polio type 2 and 3 eradication: Relevance to the immunity status of individuals living in Germany, 2005-2020.
Kohmer, Niko; Rabenau, Holger F; Rilling, Veronika; Ciesek, Sandra; Enders, Martin; Eggers, Maren.
Afiliación
  • Kohmer N; Institute for Medical Virology, University Hospital, Goethe University Frankfurt am Main, 60596, Frankfurt, Germany. Electronic address: Niko.kohmer@kgu.de.
  • Rabenau HF; Institute for Medical Virology, University Hospital, Goethe University Frankfurt am Main, 60596, Frankfurt, Germany.
  • Rilling V; Laboratory Prof. Gisela Enders MVZ GbR, 70193, Stuttgart, Germany.
  • Ciesek S; Institute for Medical Virology, University Hospital, Goethe University Frankfurt am Main, 60596, Frankfurt, Germany; German Centre for Infection Research, External Partner Site, 60323, Frankfurt, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), 60596, Frankfurt, Germ
  • Enders M; Laboratory Prof. Gisela Enders MVZ GbR, 70193, Stuttgart, Germany.
  • Eggers M; Laboratory Prof. Gisela Enders MVZ GbR, 70193, Stuttgart, Germany.
J Clin Virol ; 164: 105471, 2023 07.
Article en En | MEDLINE | ID: mdl-37130476
Since October 2019, poliovirus type 3 (PV3) has been certified as globally eradicated, and further laboratory use of PV3 will be restricted according to the WHO Polio Eradication Initiative and containment measures. To examine a possible gap in PV3 immunity and a lack of immunity against poliovirus type 2 (PV2), which was already declared as eradicated in 2015, neutralising antibodies against polioviruses (PV) of individuals living in Germany (n = 91,530 samples; mainly outpatients (≈90%) who received immune status testing) were investigated from 2005 to 2020 (age distribution: <18 years 15.8%, 18-64 years 71.2% and ≥65 years 9.5% for 2005-2015; <18 years 19.6%, 18-64 years 67% and ≥65 years 11.5% for 2016-2020). The results showed that the proportion of sera exclusively lacking antibodies against PV3 was 10.6% in 2005-2015 and 9.6% in 2016-2020 and against PV2 2.8% in 2005-2015. As there is decreased protection against PV3 and to detect potential antigenically (immune escape) variant PVs not covered by used vaccines, we recommend continued testing of PV1 and PV3.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Poliomielitis / Poliovirus Límite: Adolescent / Humans País/Región como asunto: Europa Idioma: En Revista: J Clin Virol Asunto de la revista: VIROLOGIA Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Poliomielitis / Poliovirus Límite: Adolescent / Humans País/Región como asunto: Europa Idioma: En Revista: J Clin Virol Asunto de la revista: VIROLOGIA Año: 2023 Tipo del documento: Article